Clinical Trials on Parkinson Disease (PD)

Total 376807 results

University of Florida

Completed

CODY (Co-design for You): An Immersive Technology Tool for Experiencing and Assessing Home Alterations

Parkinson Disease (PD)

United States
Chang Gung University

Completed

Gait Initiation Difficulty and Anticipatory Postural Adjustment (APA) Impairment in People With PD - Evaluation and Training

Parkinson Disease(PD)

Taiwan
IRCCS San Raffaele Roma

Completed

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients (PARKONTHEWAY)

Parkinson Disease (PD) | Paralysis; Supranuclear

Italy
Altec Inc.
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

A Smartphone Application for Neurology and Telemedicine (NeuroVision)

Parkinson Disease(PD)

United States
Federal University of Rio Grande do Sul
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.; University of...

Completed

Effects of Dance on the Turning Characteristics of Patients With Parkinson's Disease

Parkinson Disease(PD)

Brazil, United Kingdom
AbbVie

Completed

Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

Parkinson Disease (PD)

Canada
Chang Gung University

Completed

Cycling and Treadmill With Dual Task for Parkinson's Disease Improvement

Parkinson Disease(PD)

Taiwan
Stanford University

Completed

The Stanford Parkinson's Disease Plasma Study (SPDP)

Parkinson Disease(PD)

United States
Beijing Tiantan Hospital

Recruiting

EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease

PD - Parkinson's Disease

China
AbbVie

Active, not recruiting

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
AbbVie

Completed

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
AbbVie

Recruiting

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (ROSSINI)

Parkinson's Disease (PD)

Germany, Denmark, Spain
Beijing Tiantan Hospital

Recruiting

Effects of Propofol on Brain Function in Patients With Parkinson's Disease

PD - Parkinson's Disease

China
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Baylor College of Medicine

Completed

MER Versus MRI Guidance DBS in Parkinson's Disease

Idiopathic Parkinson's Disease (PD)

United States
AbbVie

Recruiting

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

Japan
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
AbbVie

Completed

COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel (COSMOS)

Parkinson's Disease (PD)

Austria, Canada, Croatia, Czechia, Greece, Hungary, Ireland, Israel, Romania, Spain, Sweden
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

United States
AbbVie

Completed

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Parkinson's Disease (PD)

United States
Bastyr University
National Center for Complementary and Integrative Health (NCCIH)

Completed

Intranasal Glutathione in Parkinson's Disease

Parkinson's Disease (PD)

United States
Chang Gung University

Recruiting

AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson's Disease

Parkinson Disease(PD)

Taiwan
Bial - Portela C S.A.

Completed

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Parkinson's Disease (PD)
Chang Gung University

Completed

Central and Peripheral Fatigue in Individuals With Parkinson's Disease - Evaluation and Training

Parkinson Disease(PD)

Taiwan
Chang Gung University

Completed

Establishing the Central and Peripheral Fatigue Indexes and VR Based Anti-fatigue Training Paradigm for Individuals With Parkinson Disease

Parkinson's Disease (PD)

Taiwan
AbbVie

Completed

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy (BALANCE)

Parkinson's Disease (PD)

Germany, Switzerland
Boston Scientific Corporation

Recruiting

Coordinated Reset Deep Brain Stimulation (RESET-DBS)

Parkinson's Disease (PD)

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Beijing Tiantan Hospital

Recruiting

Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disease (CHAMPION)

Desflurane | Dexmedetomidine | Deep Brain Stimulation | PD - Parkinson's Disease

China
Changhua Christian Hospital
Bened Biomedical Co., Ltd.

Withdrawn

Efficacy of Probiotics for Parkinson Disease (PD)

Depression | Movement Disorders | Anxiety | Parkinson's Disease (PD)

Taiwan
Bial - Portela C S.A.

Completed

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
AbbVie

Completed

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) (DYSCOVER)

Parkinson's Disease (PD)

United States, Finland, Greece, Hungary, Italy, Slovakia, Spain
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
Tel-Aviv Sourasky Medical Center

Recruiting

EMG to Detect and Monitor Freezing of Gait Among People With Parkinson's Disease

Evaluation of Muscle Contraction in People With PD

Israel
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
National Institute of Neurological Disorders and...

Completed

Genetic Characterization of Parkinson's Disease

Parkinson Disease | Healthy Volunteer | Movement Disorder | PD | HV

United States
Escape Bio, Inc.
Momentum Pharma; Science 37

Terminated

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene

United States
ACADIA Pharmaceuticals Inc.

Completed

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

United States
Tel-Aviv Sourasky Medical Center

Unknown

White Matter Pathology in Parkinson's Disease (PD)

White Matter Lesions | Postural Instability Gait Disorders

Israel
Fondazione Don Carlo Gnocchi Onlus
University of Milano Bicocca; Università Carlo Cattaneo , Castellanza

Unknown

An Innovative Disease-net Management Model for Non-communicable Diseases (SIDERA^B) (SIDERA^B)

Chronic Obstructive Pulmonary Disease (COPD) | Chronic Heart Failure (CHF) | Parkinson Disease (PD)

Italy

3

Subscribe